ULTRAGENYX PHARMACEUTICAL INC. Variable Lease, Cost
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Variable Lease, Cost of $5.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. variable lease, cost for the quarter ending 2019-12-31 was $828.00K.
- ULTRAGENYX PHARMACEUTICAL INC. variable lease, cost for the quarter ending 2019-09-30 was $630.00K.
- ULTRAGENYX PHARMACEUTICAL INC. variable lease, cost for the quarter ending 2019-06-30 was $669.00K.
- ULTRAGENYX PHARMACEUTICAL INC. variable lease, cost for the quarter ending 2019-03-31 was $652.00K.
- ULTRAGENYX PHARMACEUTICAL INC. variable lease, cost for fiscal 2025 was $5.00M, a 16.67% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. variable lease, cost for fiscal 2024 was $6.00M, a 20.00% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. variable lease, cost for fiscal 2023 was $5.00M, a 4.49% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. variable lease, cost for fiscal 2022 was $4.79M, a 15.52% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $5.00M 10-K · filed 2026-02-18 | ||||
| 2024-12-31 | $6.00M 10-K · filed 2026-02-18 | $5.89M 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $5.00M 10-K · filed 2026-02-18 | $5.27M 10-K · filed 2024-02-21 | |||
| 2022-12-31 | $4.79M 10-K · filed 2025-02-19 | ||||
| 2021-12-31 | $4.14M 10-K · filed 2024-02-21 | ||||
| 2020-12-31 | $3.30M 10-K · filed 2023-02-17 | ||||
| 2019-12-31 | $828.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $1.46M derived: sum of 2 quarters · filed 2021-02-12 | $2.13M derived: sum of 3 quarters · filed 2021-02-12 | $2.78M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $630.00K 10-Q · filed 2019-11-06 | $1.30M derived: sum of 2 quarters · filed 2019-11-06 | $1.95M 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | $669.00K 10-Q · filed 2019-08-02 | $1.32M 10-Q · filed 2019-08-02 | |||
| 2019-03-31 | $652.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |